The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database

In the era of precision medicine an increasing number of predictive biomarkers was clinically approved by international scientific societies to select advanced Non-Small Cell Lung Cancer (NSCLC) patients who are eligible for targeted therapies [1 –3]. In this rapidly evolving scenario, a plethora of diagnostic specimens must be available for both morphological and molecular evaluation in order to optimize the therapeutic management of NSCLC patients [4,5] Of note, adequacy of tissue samples represents one of the main gaps limiting biomarke r testing in metastatic NSCLC, because scant biological specimens occur in a not negligible percentage of cases (20–25 %) [6–8].

Source: Lung Cancer - April 4, 2024 Category: Cancer & Oncology Authors: Umberto Malapelle, Francesco Passiglia, Francesco Pepe, Pasquale Pisapia, Maria Lucia Reale, Diego Cortinovis, Filippo Fragetta, Domenico Galetta, Edoardo Garbo, Paolo Graziano, Fabio Pagni, Giulia Pasello, Pierluigi Piovano, Sara Pilotto, Marcello Tiseo, Tags: Research Paper Source Type: research